Target intelligence / Profile preview

microRNA let-7c (MIRLET7C)

Target
MIRLET7C
Molecular classification
microRNA, Non-coding RNA, Regulatory RNA
01

Overview

microRNA let-7c is a non-coding RNA and member of the highly conserved let-7 family of microRNAs, originally discovered for its role in developmental timing. In humans, let-7c acts as a post-transcriptional regulator by binding to the 3’ untranslated regions of target mRNAs, repressing genes involved in cell proliferation and differentiation such as MYC, RAS, and CDC25A. Let-7c is widely recognized as a tumor suppressor, commonly downregulated in various cancers including prostate cancer and hepatocellular carcinoma, where its restoration inhibits tumor cell proliferation, induces apoptosis, and suppresses tumor growth in vivo. Let-7c also plays key roles in neural differentiation and is implicated in disease processes beyond cancer, including as a biomarker and potential therapeutic target[1][2][4][5][6][12][13].

Other names
hsa-let-7cLET7CMIRNLET7Clet-7cMIRLET7C-1MIRLET7C-2
02

Mechanism of action

Silencing of target oncogenes (e.g., MYC, RAS, AR, CDC25A) via mRNA degradation or translational repression[1][2][4][12]. Negative feedback on Lin28/let-7c axis[2].

03

Biological functions

Regulation of cell differentiationControl of stem-cell divisionCell cycle regulationTumor suppressionRegulation of cell proliferationInduction of apoptosisNeuronal differentiation
04

Disease associations

CancerProstate cancerHepatocellular carcinomaLeukemiaOther solid tumorsNeurodegenerative disease
05

Safety considerations

Potential off-target effects due to broad regulatory network of miRNAsTherapeutic delivery challenges (stability, specificity, tissue targeting)Unknown long-term effects of miRNA mimic/replacement therapy[2]
06

Interacting drugs

None specifically approved or widely used; experimental delivery of let-7c mimics in preclinical studies[2][12].
07

Biomarkers

Downregulation of let-7c as a biomarker for prostate cancer progression[2]Decreased expression in hepatocellular carcinoma and other tumors[4][13]

Beyond the preview

Go deeper on microRNA let-7c (MIRLET7C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA let-7c (MIRLET7C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call